Investor Relations

Amicus Therapeutics (NASDAQ: FOLD) is pioneering a paradigm-shifting approach to treating a range of human genetic diseases in which crucial proteins are misfolded, thus reducing or eliminating their functionality. Amicus develops pharmacological chaperones - oral therapies that bind to and stabilize the affected proteins, restoring their shape, proper trafficking, and biological activity. This novel, next-generation approach offers the potential to improve treatment options for patients with genetic diseases.

Recent Releases

Mar 2, 2010
Amicus Therapeutics Announces Closing of $18.5 Million Registered Direct Offering of Common Stock

Feb 25, 2010
Amicus Therapeutics Announces $18.5 Million Registered Direct Offering of Common Stock

Events

Feb 16, 2010
Amicus Therapeutics Fourth Quarter 2009 Results Conference Call

Jan 11, 2010
28th Annual J.P. Morgan Healthcare Conference